COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that data from a 53-patient double-blind, placebo controlled trial studying the treatment of heart attack patients with Prochymal, a proprietary formulation of mesenchymal stem cells (MSCs), as well as research on the underlying mechanism of action of MSCs for cardiac repair, will be presented at the 2010 BMT Tandem Meeting. Joshua M. Hare, M.D., Louis Lemberg Professor of Medicine (Cardiology) and Director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine, will present the data during a session entitled “Cardiac Stem Cell Therapy” on Thursday, February 25. Results from the study were recently published in the Journal of the American College of Cardiology (JACC).
